Progenity Inc. (PROG): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROG POWR Grades
- PROG scores best on the Growth dimension, with a Growth rank ahead of 87.71% of US stocks.
- The strongest trend for PROG is in Growth, which has been heading up over the past 179 days.
- PROG's current lowest rank is in the Stability metric (where it is better than 1.36% of US stocks).
PROG Stock Summary
- PROG's price/sales ratio is 183.09; that's higher than the P/S ratio of 98.56% of US stocks.
- Revenue growth over the past 12 months for Progenity Inc comes in at -98.32%, a number that bests only 0.8% of the US stocks we're tracking.
- In terms of volatility of its share price, PROG is more volatile than 95.79% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Progenity Inc are WISA, ACAD, PGEN, TMDX, and GPRO.
- To check out Progenity Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001580063.
PROG Valuation Summary
- PROG's price/earnings ratio is -0.3; this is 100.82% lower than that of the median Healthcare stock.
- PROG's price/sales ratio has moved down 3 over the prior 15 months.
- PROG's price/earnings ratio has moved up 2.3 over the prior 15 months.
Below are key valuation metrics over time for PROG.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PROG | 2021-08-31 | 1.1 | -0.5 | -0.3 | -0.7 |
| PROG | 2021-08-30 | 1.0 | -0.5 | -0.3 | -0.7 |
| PROG | 2021-08-27 | 0.9 | -0.4 | -0.3 | -0.7 |
| PROG | 2021-08-26 | 0.9 | -0.4 | -0.3 | -0.7 |
| PROG | 2021-08-25 | 1.0 | -0.5 | -0.3 | -0.7 |
| PROG | 2021-08-24 | 1.0 | -0.5 | -0.3 | -0.7 |
PROG's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PROG has a Quality Grade of D, ranking ahead of 11.47% of graded US stocks.
- PROG's asset turnover comes in at 0.499 -- ranking 52nd of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows PROG's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.499 | -0.031 | -2.008 |
| 2021-03-31 | 0.557 | -0.086 | -2.222 |
| 2020-12-31 | 0.520 | -0.257 | -2.891 |
PROG Price Target
For more insight on analysts targets of PROG, see our PROG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1.62 (Moderate Buy) |
PROG Stock Price Chart Interactive Chart >
PROG Price/Volume Stats
| Current price | $0.88 | 52-week high | $6.20 |
| Prev. close | $0.92 | 52-week low | $0.66 |
| Day low | $0.84 | Volume | 2,779,600 |
| Day high | $0.92 | Avg. volume | 8,589,605 |
| 50-day MA | $1.17 | Dividend yield | N/A |
| 200-day MA | $1.85 | Market Cap | 162.92M |
Progenity Inc. (PROG) Company Bio
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
Latest PROG News From Around the Web
Below are the latest news stories about Progenity Inc that investors may wish to consider to help them evaluate PROG as an investment opportunity.
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitisSAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congre |
Progenity (PROG) Receives a Buy from H.C. WainwrightE…. |
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of GastroenterologyDr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022. During the oral presentation t |
10 Stocks to Buy That Could Make You a Millionaire in 2022After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022. |
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional PatentSAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t |
PROG Price Returns
| 1-mo | N/A |
| 3-mo | -24.14% |
| 6-mo | -57.89% |
| 1-year | -75.28% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -57.89% |
| 2021 | -60.64% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...